Published Study Demonstrates the Association Between Immunovaccine’s Proprietary Immune-targeted Delivery Technology

Immunovaccine (TSX:IMV) a clinical stage immuno-oncology company, announced the publication of a preclinical study using magnetic resource imaging (MRI) to...

Provectus Biopharmaceuticals Reports Data On PV-10 in Combination Therapy and T Cell Mediated Immunity Presented at American Association for Cancer Research (AACR) Annual Meeting 2016

KNOXVILLE, Tenn.–(BUSINESS WIRE)–Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or “The Company”), announced...